76 completed, 5 unknown, 4 terminated, 1 not yet recruiting. 89 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 89 | Completed 76, Unknown 5, Terminated 4, Not yet recruiting 1, Recruiting 1, Suspended 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Not yet recruiting 1, Terminated 1 |
Follow Hydrochlorothiazide: new trials by email Literature Review of Hydrochlorothiazide trials Research Report on Hydrochlorothiazide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure Furosemide 40 Milligrams., Hydrochlorothiazide (HCTZ) 25 milligrams., Acetazolamide 250 milligrams. - Acute Heart Failure (AHF), Congestive Heart Failure Acute | Phase 2 / Phase 3 | Not yet recruiting | Hospital de Clinicas de Porto Alegre | 128 | 2026-03-23 | 2026-03-18 |
| HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life Hydrochlorothiazide 25 mg, Placebo - ADPKD | Phase 3 | Recruiting | University Medical Center Groningen | 300 | 2024-07-31 | 2026-08-25 |
| Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension candesartan cilexetil + chlorthalidone + amlodipine, Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg) - Hypertension | Phase 3 | Completed | Hospital Israelita Albert Einstein | 702 | 2023-08-22 | 2025-07-09 |
| Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension Sacubitril/valsartan, valsartan - Resistant Hypertension | Phase 3 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 138 | 2022-09-24 | 2022-09-19 |
| Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension Losartan/Chlorthalidone in fixed dose, Losartan + hydrochlorothiazide in fixed dose - Essential Arterial Hypertension | Phase 3 | Completed | Laboratorios Silanes S.A. de C.V. | 163 | 2022-06-30 | 2025-03-13 |
| Early Sequential Nephron Blockade in Acute Heart Failure Patients: A Randomised, Controlled Study Spironolactone or hydrochlorothiazide, Placebo - Acute Heart Failure, Acute Kidney Injury | Phase 3 | Unknown | Chiang Mai University | 100 | 2020-08-13 | 2020-08-18 |
| Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment Indapamide / Losartan, Hyzaar® - Hypertension | Phase 3 | Suspended | EMS | 636 | 2019-11-27 | 2022-07-27 |
| Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on Blood Pressure in Primary Hypertension. Chlorthalidone 25 mg, Hydrochlorothiazide 50 mg, Amiloride 20 mg - Hypertension | Phase 3 | Unknown | Hospital de Clinicas de Porto Alegre | 84 | 2019-11-13 | 2019-12-09 |
| Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide Hydrochlorothiazide 50mg Tablet, Placebo Tablet - Pre-Eclampsia, Gestational Hypertension | Phase 3 | Terminated | The University of Texas Medical Branch, Galveston | 453 | 2017-11-21 | 2026-07-14 |
| Hydrochlorothiazide for Kidney Stone Recurrence Prevention Placebo oral capsule, 12.5 mg hydrochlorothiazide, 25.0 mg hydrochlorothiazide - Nephrolithiasis | Phase 3 | Completed | Insel Gruppe AG, University Hospital Bern | 416 | 2017-03-09 | 2024-02-01 |
| Randomized Controlled Trial of Renal Denervation for Resistant Hypertension Radiofrequency ablation catheter, Amlodipine, losartan potassium and hydrochlorothiazide - Hypertension | Phase 3 | Unknown | Shanghai WiseGain Medical Devices Co., Ltd. | 254 | 2016-10-01 | 2016-09-14 |
| Fimasartan in the Senior Subjects Fimasartan or Fimasartan/Hydrochlorothiazide, Perindopril or Perindopril/Indapamide - The Elderly (≥ 70 Years) With Essential Hypertension | Phase 3 | Completed | Boryung Pharmaceutical Co., Ltd | 241 | 2016-07-15 | 2020-03-23 |
| Diuretic Comparison Project Hydrochlorothiazide (HCTZ), Chlorthalidone (CTD) - Hypertension | Phase 3 | Completed | VA Office of Research and Development | 20723 | 2016-06-15 | 2024-05-22 |
| Pharmacogenomics of Hypertension Personalized Medicine (PGX-HT) Peri, HCTZ - Hypertension | Phase 3 | Unknown | Ospedale San Raffaele | 300 | 2016-03-01 | 2017-08-15 |
| Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients Telmisartan/Amlodipine+Hydrochlorothiazide, Telmisartan/Amlodipine, Placebo for Hydrochlorothiazide - Essential Hypertension | Phase 3 | Completed | IlDong Pharmaceutical Co Ltd | 300 | 2015-05-01 | 2016-11-25 |
| A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension TAK-536TCH tablet, TAK-536CCB tablet, HCTZ 12.5 mg tablet - Essential Hypertension | Phase 3 | Completed | Takeda | 341 | 2014-11-07 | 2017-08-02 |
| Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure hydrochlorothiazide, Placebo - Heart Failure | Phase 3 | Completed | Spanish Society of Internal Medicine | 232 | 2014-10-01 | 2022-10-04 |
| Enalapril Folic Acid Tablets Combined With CCB or Diuretic to Prevent Stroke in Patients With Type H Hypertension Enalapril Folic Acid Tablets Combined With amlodipine, Enalapril Folic Acid Tablets Combined With hydrochlorothiazide - Hypertension | Phase 3 | Completed | Second Affiliated Hospital, Zhejiang University, School of Medicine | 1000 | 2014-07-01 | 2021-07-23 |
| Add-on to Micamlo BP Trial Telmisartan + amlodipine, hydrochlorothiazide, Placebo - Hypertension | Phase 3 | Completed | Boehringer Ingelheim | 309 | 2013-11-01 | 2016-11-29 |
| Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine placebo, telmisartan + HCTZ, amlodipine - Hypertension | Phase 3 | Completed | Boehringer Ingelheim | 132 | 2013-07-01 | 2016-03-28 |
Showing 20 of 89. Sign in to see all of them.
Hypertension (64) · Essential Hypertension (19) · Cardiovascular Diseases (5) · Vascular Diseases (3) · Atherosclerosis (2) · Diabetes Mellitus, Type 2 (2) · Heart Failure (2) · Isolated Systolic Hypertension (2) · Nephrolithiasis (2) · Acute Kidney Injury (1) · Coronary Disease (1) · Death, Sudden, Cardiac (1) · Dent Disease (1) · Diabetes Mellitus (1) · Heart Arrest (1)
Novartis (21) · Boehringer Ingelheim (9) · Daiichi Sankyo (6) · Organon and Co (6) · Takeda (6) · AstraZeneca (3) · Novartis Pharmaceuticals (3) · Sankyo Pharma Gmbh (3) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (2) · EMS (2) · Hospital de Clinicas de Porto Alegre (2) · Merck Sharp & Dohme LLC (2) · Pfizer (2) · Assistance Publique - Hôpitaux de Paris (1) · Boryung Pharmaceutical Co., Ltd (1)
Germany (29) · United States (20) · Switzerland (13) · Netherlands (12) · Spain (10) · Denmark (8) · France (8) · Japan (8) · Poland (8) · Belgium (7) · Italy (7) · Canada (6) · Slovakia (6) · Sweden (6) · Brazil (5)
Peter U Witte, MD, Ph.D. (2) · Professor Lars Christian Rump, M.D. (2) · Aaron S Kelly, PhD (1) · Areef Ishani, MD MS (1) · Benjamin Bush, M.D. (1)
PMID 22114906, PMID 15539615, PMID 17922981, PMID 18326958, PMID 18463672, PMID 18539917, PMID 18593517, PMID 18761785, PMID 18976849, PMID 19052124, PMID 19191674, PMID 19257800, PMID 19751459, PMID 19898642, PMID 20061358, PMID 20061360, PMID 20170948, PMID 20215456, PMID 20228401, PMID 20228404, PMID 20427682, PMID 20571135, PMID 20587587, PMID 20594588, PMID 20620720, PMID 20678674, PMID 21062137, PMID 21236483, PMID 21248785, PMID 21366473, PMID 21663644, PMID 21910510, PMID 21958949, PMID 22019270, PMID 22049171, PMID 22179956, PMID 22374637, PMID 22381711, PMID 22432114, PMID 22450889, PMID 22515638, PMID 22608107, PMID 22619083, PMID 22646230, PMID 22710649, PMID 22723577, PMID 22799613, PMID 22909147, PMID 22939358, PMID 23033246
2008 (2), 2009 (2), 2016 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1), R01HL036821 (1)